Navigating Policy & Regulatory Shifts: Key Considerations for Pharma GTN Teams in 2026
The pharmaceutical pricing landscape is entering a period of unprecedented change. With the Inflation Reduction Act (IRA) now active and Medicare drug price negotiations underway in 2026, GTN teams face complex challenges in forecasting, compliance, and financial planning. Add evolving Medicaid policies, PBM reforms, and international trade considerations, and the environment becomes even more intricate.
At the Pharma Biotech Gross-to-Net Summit, a dedicated series of sessions will help attendees navigate these shifts with actionable insights:
Understanding trade, supply chain impacts, and the Most Favored Nation implications on pharma operations.
A comprehensive review of healthcare policy timelines, PBM reform initiatives, and strategies for compliance across multiple programs.
Explore Medicaid rebate calculations, 340B discounts, multi-year forecasting, and scenario planning to anticipate policy-driven operational impacts.
Practical guidance on negotiations, inflation penalties, invoice monitoring, and preparing organizations for upcoming price adjustments.
Join the industry in Philadelphia, November 18 – 20
Ensure your GTN processes are compliant, resilient, and optimized for the future.
For GTN leaders, staying ahead of these policy changes is critical — and the summit provides a unique opportunity to learn directly from experts, benchmark strategies, and prepare for the evolving 2026 landscape.